168 related articles for article (PubMed ID: 36816341)
1. Polypill for atherosclerotic cardiovascular disease prevention in Haiti: Eligibility estimates in a low-income country.
Yan LD; Rouzier V; Pierre JL; Dade E; Sufra R; Huffman MD; Apollon A; St Preux S; Metz M; Sabwa S; Morisset B; Deschamps M; Pape JW; McNairy ML
Front Epidemiol; 2022; 2():. PubMed ID: 36816341
[TBL] [Abstract][Full Text] [Related]
2. Comparing six cardiovascular risk prediction models in Haiti: implications for identifying high-risk individuals for primary prevention.
Yan LD; Lookens Pierre J; Rouzier V; Théard M; Apollon A; St Preux S; Kingery JR; Jamerson KA; Deschamps M; Pape JW; Safford MM; McNairy ML
BMC Public Health; 2022 Mar; 22(1):549. PubMed ID: 35305599
[TBL] [Abstract][Full Text] [Related]
3. Projected impact of polypill use among US adults: Medication use, cardiovascular risk reduction, and side effects.
Muntner P; Mann D; Wildman RP; Shimbo D; Fuster V; Woodward M
Am Heart J; 2011 Apr; 161(4):719-25. PubMed ID: 21473971
[TBL] [Abstract][Full Text] [Related]
4. The feasibility of polypill for cardiovascular disease prevention in Asian Population.
Sukonthasarn A; Chia YC; Wang JG; Nailes J; Buranakitjaroen P; Van Minh H; Verma N; Hoshide S; Shin J; Turana Y; Tay JC; Teo BW; Siddique S; Sison J; Zhang YQ; Wang TD; Chen CH; Kario K
J Clin Hypertens (Greenwich); 2021 Mar; 23(3):545-555. PubMed ID: 33086429
[TBL] [Abstract][Full Text] [Related]
5. Polypill Programs to Prevent Stroke and Cut Costs in Low Income Countries: Moving From Clinical Efficacy to Pragmatic Implementation.
Sarfo FS; Nichols M; Opare-Addo PA; Ovbiagele B
Stroke; 2023 Feb; 54(2):407-414. PubMed ID: 36689592
[TBL] [Abstract][Full Text] [Related]
6. Population-Based Epidemiology of Heart Failure in a Low-Income Country: The Haiti Cardiovascular Disease Cohort.
Kingery JR; Roberts NL; Lookens Pierre J; Sufra R; Dade E; Rouzier V; Malebranche R; Theard M; Goyal P; Pirmohamed A; Yan LD; Hee Lee M; Nash D; Metz M; Peck RN; Safford MM; Fitzgerald D; Deschamps MM; Pape JW; McNairy M
Circ Cardiovasc Qual Outcomes; 2023 Feb; 16(2):e009093. PubMed ID: 36472189
[TBL] [Abstract][Full Text] [Related]
7. Spectrum of prevalent cardiovascular diseases in urban Port-au-Prince, Haiti: a population-based cross-sectional study.
Yan LD; Sufra R; St Sauveur R; Jean-Pierre MC; Apollon A; Malebranche R; Théard M; Pierre G; Dévieux J; Lau J; Mourra N; Roberts NLS; Rasul R; Nash D; Pirmohamed AM; Devereux RB; Lee MH; Kwan GF; Safford MM; Adrien L; Alfred JP; Deschamps M; Severe P; Fitzgerald DW; Pape JW; Rouzier V; McNairy ML;
Lancet Reg Health Am; 2024 May; 33():100729. PubMed ID: 38590326
[TBL] [Abstract][Full Text] [Related]
8. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
[TBL] [Abstract][Full Text] [Related]
9. Neighborhood Social Vulnerability and Premature Cardiovascular Disease in Haiti.
Roberts NLS; Sufra R; Yan LD; St Sauveur R; Inddy J; Macius Y; Théard M; Lee MH; Mourra N; Rasul R; Nash D; Deschamps MM; Safford MM; Pape JW; Rouzier V; McNairy ML
JAMA Cardiol; 2024 Jun; ():. PubMed ID: 38837139
[TBL] [Abstract][Full Text] [Related]
10. The concept of the polypill in the prevention of cardiovascular disease.
Wiley B; Fuster V
Ann Glob Health; 2014; 80(1):24-34. PubMed ID: 24751562
[TBL] [Abstract][Full Text] [Related]
11. Examining the Use of a Polypill in Cardiovascular Disease Prevention.
Wang A; Veasaw K; Subhan S; Patel J; Frishman WH
Cardiol Rev; 2023 Jul; ():. PubMed ID: 37401822
[TBL] [Abstract][Full Text] [Related]
12. Effectiveness of polypill for primary and secondary prevention of cardiovascular diseases (PolyIran): a pragmatic, cluster-randomised trial.
Roshandel G; Khoshnia M; Poustchi H; Hemming K; Kamangar F; Gharavi A; Ostovaneh MR; Nateghi A; Majed M; Navabakhsh B; Merat S; Pourshams A; Nalini M; Malekzadeh F; Sadeghi M; Mohammadifard N; Sarrafzadegan N; Naemi-Tabiei M; Fazel A; Brennan P; Etemadi A; Boffetta P; Thomas N; Marshall T; Cheng KK; Malekzadeh R
Lancet; 2019 Aug; 394(10199):672-683. PubMed ID: 31448738
[TBL] [Abstract][Full Text] [Related]
13. REDUCE-IT Eligibility and Preventable Cardiovascular Events in the US Population (from the National Health and Nutrition Examination Survey [NHANES]).
Wong ND; Fan W; Philip S; Granowitz C; Toth PP
Am J Cardiol; 2020 Nov; 134():62-68. PubMed ID: 32933754
[TBL] [Abstract][Full Text] [Related]
14. Mobile phone-based interventions for improving adherence to medication prescribed for the primary prevention of cardiovascular disease in adults.
Palmer MJ; Barnard S; Perel P; Free C
Cochrane Database Syst Rev; 2018 Jun; 6(6):CD012675. PubMed ID: 29932455
[TBL] [Abstract][Full Text] [Related]
15. The Haiti cardiovascular disease cohort: study protocol for a population-based longitudinal cohort.
Lookens J; Tymejczyk O; Rouzier V; Smith C; Preval F; Joseph I; Baptiste RJ; Victor J; Severe P; Apollon S; Dumont E; Forestal G; St Preux S; Rivera V; Seo G; Charles B; Ariste W; Kingery J; Devieux J; Koenig S; Nash D; Fitzgerald D; Safford M; Deschamps MM; Pape J; McNairy M
BMC Public Health; 2020 Nov; 20(1):1633. PubMed ID: 33131500
[TBL] [Abstract][Full Text] [Related]
16. Association of polypill therapy with cardiovascular outcomes, mortality, and adherence: A systematic review and meta-analysis of randomized controlled trials.
Rao S; Jamal Siddiqi T; Khan MS; Michos ED; Navar AM; Wang TJ; Greene SJ; Prabhakaran D; Khera A; Pandey A
Prog Cardiovasc Dis; 2022; 73():48-55. PubMed ID: 35114251
[TBL] [Abstract][Full Text] [Related]
17. Cost-effectiveness of a fixed-dose combination pill for secondary prevention of cardiovascular disease in China, India, Mexico, Nigeria, and South Africa: a modelling study.
Lin JK; Moran AE; Bibbins-Domingo K; Falase B; Pedroza Tobias A; Mandke CN; Kazi DS
Lancet Glob Health; 2019 Oct; 7(10):e1346-e1358. PubMed ID: 31477544
[TBL] [Abstract][Full Text] [Related]
18. Cost-effectiveness analysis of use of a polypill versus usual care or best practice for primary prevention in people at high risk of cardiovascular disease.
Jowett S; Barton P; Roalfe A; Fletcher K; Hobbs FDR; McManus RJ; Mant J
PLoS One; 2017; 12(9):e0182625. PubMed ID: 28873416
[TBL] [Abstract][Full Text] [Related]
19. Use of statins for the prevention of cardiovascular disease in 41 low-income and middle-income countries: a cross-sectional study of nationally representative, individual-level data.
Marcus ME; Manne-Goehler J; Theilmann M; Farzadfar F; Moghaddam SS; Keykhaei M; Hajebi A; Tschida S; Lemp JM; Aryal KK; Dunn M; Houehanou C; Bahendeka S; Rohloff P; Atun R; Bärnighausen TW; Geldsetzer P; Ramirez-Zea M; Chopra V; Heisler M; Davies JI; Huffman MD; Vollmer S; Flood D
Lancet Glob Health; 2022 Mar; 10(3):e369-e379. PubMed ID: 35180420
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
